vimarsana.com

21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August

Related Keywords

Austria ,Vienna ,Wien ,Prague ,Praha ,Hlavníesto ,Czech Republic ,Russia ,Salzburg ,Ukraine ,Russian ,Austrian ,Ein Fokusbereich ,Christoph Boschan ,Prague Stock Exchange Group ,Cleen Energy ,Vienna Stock Exchange ,Stock Exchange ,Pierer Mobility ,Vienna Prague Stock Exchange Group ,Central European ,Bereich Leasing ,Besuchen Sie ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.